Table.
Selected characteristics of the study cohort according to vaccine type
| mRNA-based vaccines*(n=4 116 803) | Adenovirus-vectored vaccines*(n=1 234 282) | ||
|---|---|---|---|
| Men | 1 935 105 (47·0%) | 575 869 (46·7%) | |
| Age category, years | |||
| 12–49 | 1 606 712 (39·0%) | 132 399 (10·7%) | |
| 50–59 | 886 799 (21·5%) | 236 497 (19·2%) | |
| 60–69 | 528 681 (12·8%) | 422 166 (34·2%) | |
| 70–79 | 404 455 (9·8%) | 436 013 (35·3%) | |
| ≥80 | 690 156 (16·8%) | 7207 (0·6%) | |
| Previous contacts with the Regional Health Service† | |||
| <5 | 1 500 430 (36·4%) | 431 250 (34·9%) | |
| 5–99 | 2 319 122 (56·3%) | 726 786 (58·9%) | |
| ≥100 | 297 251 (7·2%) | 76 246 (6·2%) | |
| Previous SARS-CoV-2 infection | 180 619 (4·4%) | 33 304 (2·7%) | |
| Comorbidities† | |||
| Diabetes | 343 557 (8·4%) | 56 229 (4·6%) | |
| Heart failure | 31 889 (0·8%) | 2057 (0·2%) | |
| Chronic respiratory disease | 377 205 (9·2%) | 103 027 (8·4%) | |
| Malignancies | 132 713 (3·2%) | 22 005 (1·8 %) | |
| Organ transplant | 17 184 (0·4%) | 754 (0·1%) | |
| Hypertension | 627 997 (15·3%) | 217 824 (17·7%) | |
| Vascular disease | 337 537 (8·2%) | 84 978 (6·9%) | |
| Valvular disease | 12 635 (0·3%) | 2059 (0·2%) | |
| Cerebrovascular disease | 38 675 (0·9%) | 3833 (0·3%) | |
| Chronic kidney disease | 19 709 (0·5%) | 874 (0·1%) | |
| Month of vaccine completion | |||
| January | 66 739 (1·6%) | 0 (0·0%) | |
| February | 169 198 (4·1%) | 0 (0·0%) | |
| March | 271 429 (6·6%) | 54 (<0·1%) | |
| April | 430 874 (10·5%) | 11 064 (0·9%) | |
| May | 941 385 (22·9%) | 252 439 (20·5%) | |
| June | 598 948 (14·6%) | 279 985 (22·7%) | |
| July | 1 638 230 (39·8%) | 690 740 (56·0%) | |
*
Four vaccines are currently authorised in Italy, two of them are mRNA-based (ie, those manufactured by Pfizer-BioNTech and Moderna) and the other two are adenovirus-vectored (ie, those manufactured by Oxford-AstraZeneca and Janssen).
†
Measured in the 2-year period before the index date.